Treatment Overview

Undergoing fertility treatments represents a journey of hope and dedication, but developing Ovarian Hyperstimulation Syndrome (OHSS) can feel like a frightening and physically demanding setback. This condition, where the ovaries become swollen and painful due to elevated hormone levels, typically occurs after egg stimulation. Symptoms range from mild abdominal bloating and nausea to severe fluid retention and breathing difficulties. While the physical discomfort can be overwhelming, the condition is temporary and generally resolves on its own with appropriate support.

Treatment is critical to manage pain, maintain hydration, and prevent serious complications such as blood clots or kidney strain. The primary objective is to support the body while the ovaries return to their normal size and hormone levels stabilize. Because OHSS can range from a nuisance to a medical emergency, treatment plans are highly adaptable. Mild cases are often managed at home with monitoring, while severe cases may require hospitalization and intensive pharmacological support (American Society for Reproductive Medicine, 2021).

Overview of treatment options for Ovarian Hyperstimulation Syndrome

The management of OHSS is primarily supportive, meaning the goal is to relieve symptoms and prevent complications rather than to “cure” the syndrome instantly, as it must run its course. Treatment focuses on managing fluid shifts within the body, controlling pain, and reducing the risk of thrombosis (blood clots).

For mild to moderate cases, the approach involves oral fluids, rest, and basic symptom management. However, when the condition escalates, doctors utilize specific medications to dampen the physiological response and protect vital organs. Procedures like paracentesis (draining excess fluid from the abdomen) are used only when necessary to improve breathing or severe discomfort, but medication remains the daily standard for management.

Medications used for Ovarian Hyperstimulation Syndrome

Pharmacological treatment for OHSS addresses four main areas: reducing the biological trigger, managing pain, preventing clots, and stabilizing fluids.

To reduce the severity of the syndrome, doctors often prescribe dopamine agonists, such as cabergoline. This medication is frequently started at the time of the trigger shot or immediately upon diagnosis. Clinical studies suggest that cabergoline can significantly reduce the incidence of moderate to severe OHSS by targeting the underlying mechanism of vascular leakage.

For pain management, simple analgesics are the first line of defense. Acetaminophen is typically preferred over non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, especially if there is a possibility of pregnancy or concern about kidney function.

Because OHSS causes the blood to thicken, increasing the risk of dangerous clots, anticoagulants are a critical part of treatment for moderate to severe cases. Low-molecular-weight heparins, such as enoxaparin, are commonly injected daily.

In a hospital setting, intravenous (IV) fluids containing albumin may be administered. Additionally, anti-emetics like ondansetron are prescribed to control the severe nausea and vomiting that often accompany the ovarian swelling (Mayo Clinic, 2023).

How these medications work

Dopamine agonists like cabergoline work by inhibiting a specific protein called Vascular Endothelial Growth Factor (VEGF). In OHSS, the ovaries release excessive VEGF, which makes blood vessels “leaky.” This leakiness allows fluid to escape the bloodstream and accumulate in the abdomen and chest. By blocking this factor, cabergoline helps seal the vessels and reduces fluid buildup.

Anticoagulants thin the blood to prevent it from clotting in the deep veins, a risk that is heightened by both the high estrogen levels and the dehydration associated with OHSS. Albumin acts as a volume expander; it increases the concentration of protein in the blood, which acts like a magnet to pull leaking fluid back into the blood vessels where it belongs, helping to maintain blood pressure and kidney flow.

Side effects and safety considerations

Treatments for OHSS are generally safe but require careful monitoring. Dopamine agonists may cause dizziness, headache, or low blood pressure. Anticoagulants risk bruising or bleeding.

Safety monitoring for fluid intake is essential. While hydration is key, excessive plain water can worsen electrolyte imbalances; strict medical guidance on fluid limits and types is often necessary. Patients must avoid NSAIDs unless approved, as they can affect kidney function. Seek immediate medical care for shortness of breath, severe chest pain, or sudden decreased urination, which may signal worsening fluid retention or a clot (Cleveland Clinic, 2022).

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. American Society for Reproductive Medicine. https://www.asrm.org
  2. Cleveland Clinic. https://my.clevelandclinic.org
  3. Mayo Clinic. https://www.mayoclinic.org
  4. MedlinePlus. https://medlineplus.gov

Medications for Ovarian Hyperstimulation Syndrome

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Ovarian Hyperstimulation Syndrome.

Found 1 Approved Drug for Ovarian Hyperstimulation Syndrome

Citrtae

Brand Names
MiloPhene, Clomid

Citrtae

Brand Names
MiloPhene, Clomid
Form: Tablet
Method of administration: Oral
FDA approval date: September 09, 2022
Classification: Estrogen Agonist/Antagonist
Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome, amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS.) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below: 1. Patients who are not pregnant. 2. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. 3. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. 4. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: 1. Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. 2. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. 3. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. 4. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. 5. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses.
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances